CEO SUMMARY: There was an interesting blend of anxiety and optimism as a record crowd gathered in New Orleans last week for the 18th annual Executive War College on Laboratory and Pathology Management. The anxiety was rooted in the shrinking prices paid by payers for lab testing services. The optimism was based on recognition that
Tag: laboratory executive
CEO SUMMARY: How is it that some commercial payers for one lab running molecular tests have continued to pay the lab for tests it has run this year, but contractors for CMS have so far failed to pay? That’s the question one lab CEO is asking. Both the commercial payers and the CMS contractors are
There is confusion and disruption in the molecular testing sector of the clinical lab testing industry. That’s because both government and private payers were not ready to process and reimburse for the 100+ new molecular CPT test codes on January 1, 2013.
That is the date when the Medicare program was supposed to be ready to
CEO SUMMARY: California will operate one of the nation’s largest health insurance benefit exchanges, as defined by the Affordable Care Act. Officials recently unveiled details about the exchange, to be called Covered California. Based on bronze, silver, gold, or platinum plan coverage, beneficiaries will be required to pay a copay of between $6 and $45
CEO SUMMARY: A recent report by a consulting firm that tracks the ACO industry indicates that, as of the end of 2012, ACOs of all types involved—in some manner—between 25 and 31 million patients. Moreover, Medicare and private ACOs are located in regions where 45% of the population of the United States lives. These facts
IT IS SELDOM THAT THE CLINICAL LABORATORY INDUSTRY HITS THE RADAR SCREEN during a presidential election. So it is with some interest that I report to you that Mitt Romney recently touted the lessons he learned while serving on the board of Damon Clinical Laboratories, Inc., as useful for guiding the nation.
Romney, now the Republican
CEO SUMMARY: From the perspective of the average citizen, it would appear that Quest Diagnostics scored two major “wins” over the California Attorney General in the negotiations as to how the whistleblower lawsuit was to be settled. Language in the settlement agreement would indicate that current lab sales and marketing practices involving deeply-discounted test prices
CEO SUMMARY: Pathologists, clinical lab executives, and lawyers in California are going to find some surprises when they study the “Settlement Agreement and Release” that was recently signed by the California Attorney General and Quest Diagnostics Incorporated. Quest Diagnostics has indeed agreed to pay $241 million to resolve the allegations in the whistleblower lawsuit. But
CEO SUMMARY: It is now possible to see the specific language in the “Settlement Agreement and Release” document executed by the California State Attorney General and Quest Diagnostics Incorporated. For those clinical lab managers—and the attorneys who represent their laboratory companies—there is mixed news and guidance about 51501(a) from this agreement. That’s because, while assenting
CEO SUMMARY: It was on May 19 that the California Attorney General and Quest Diagnostics Incorporated signed an agreement to settle allegations that Quest Diagnostics overcharged Medi-Cal, the state’s Medicaid program. It is expected that the California Attorney General will now move to resolve the whistleblower case against the remaining lab company defendants. Meanwhile, similar